Observer blinded, randomized phase 3 study to investigate the non-inferiority of IC51 vs. JE-VAX as vaccines for Japanese encephalitis in healthy subjects

Trial Profile

Observer blinded, randomized phase 3 study to investigate the non-inferiority of IC51 vs. JE-VAX as vaccines for Japanese encephalitis in healthy subjects

Completed
Phase of Trial: Phase III

Latest Information Update: 02 Nov 2013

At a glance

  • Drugs IC 51 (Primary) ; Japanese encephalitis vaccine
  • Indications Encephalitis virus infections
  • Focus Pharmacodynamics; Registrational
  • Sponsors Valneva
  • Most Recent Events

    • 11 Nov 2008 Results published in Vaccine, according to 1102799.
    • 01 Dec 2007 Primary endpoint met; results reported in The Lancet.
    • 21 Oct 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top